In a meta-analysis [20] of the relationship between the administration of interleukin-6 antagonists and mortality among hospitalized patients with COVID-19, a combination of interleukin-6 antagonists and corticosteroids was associated with lower 28-day mortality than corticosteroids or interleukin-6 antagonists alone. Here, IL6 is linked to COVID-19.